#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Ash Bassett Email
VP, Finance . Eupraxia Pharmaceuticals
How to contact Ash Bassett
Join and see Ash's contact info for free!Current Roles
Employees:
39Revenue:
$3.5MAbout
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia’s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.Eupraxia Pharmaceuticals Address
2590 Cadboro Bay RdVictoria, BC